

## **Initial Dose Escalation Visit**

#### Patient name

Date of birth (mm/dd/yyyy)

Date of service (mm/dd/yyyy)

**Note:** The patient should receive sequential increasing doses of PALFORZIA beginning at level A. Each dose should be separated by an observation period of 20 to 30 minutes. No dose level should be omitted. Following completion of the last dose (level E), the patient should be observed for at least 60 minutes until suitable for discharge per treating healthcare provider.

Dose Level	Date of Service	Total Dose	Dose Configuration (in capsules)	Observation Time After Dose (minutes)	<b>Observation Notes</b> (e.g., tolerability, reactions, discontinue therapy, clear for next dose, etc.)
А		0.5 mg	1 x 0.5 mg		
в		1 mg	lxlmg		
с		1.5 mg	1 x 0.5 mg; 1 x 1 mg		
<b>D</b> (if tolerated, cleared to Up- Dosing phase)		3 mg	3 x l mg		
Е		6 mg	6 x 1 mg		

#### Important Reminders<sup>1</sup>:

- Discontinue PALFORZIA if symptoms requiring medical intervention (e.g., use of epinephrine) occur with any dose during Initial Dose Escalation
- Discontinue treatment with PALFORZIA for patients who are unable to tolerate doses up to and including the 3-mg dose during
- Initial Dose Escalation • If possible, begin Up-Dosing the day after Initial Dose Escalation
- Repeat Initial Dose Escalation in a healthcare setting if the patient is unable to begin Up-Dosing within 4 days
- Ensure the patient has injectable epinephrine and instruct the patient, parent, or guardian on its proper use



## PALFORZIA PATIENT DOSING HISTORY (CONTINUED)

## **Up-Dosing Visits**

Report each Up-Dosing visit in the patient's medical record.

Dose Level (1-11)	Date of Service	Total Dose	Dose Configuration	<b>Observation</b> <b>Time After Dose</b> (minutes)	<b>Observation Notes</b> (e.g., repeating level, down-level, discontinue therapy)

#### Discontinue treatment with PALFORZIA for<sup>1</sup>:

- Patients with suspected eosinophilic esophagitis
- Patients unable to comply with the daily dosing requirements
- Patients with recurrent asthma exacerbations or persistent loss of asthma control

# Please see full <u>Prescribing Information</u>, including Boxed WARNING, and <u>Medication Guide</u> at PALFORZIAPro.com.

Reference: 1. PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc.

